Novartis: Muscular Atrophy trials

The registry lists 13 Muscular Atrophy studies with Novartis as lead sponsor. 1 are open to participants now and 11 have results posted.

Phase 2 5Phase 3 6Phase 4 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated With ZolgensmaRecruitingNCT06019637
• Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or RisdiplamCompletedNCT05386680Phase 3Results posted
• Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)CompletedNCT05089656Phase 3Results posted
• Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA)CompletedNCT05073133Phase 4Results posted
• Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)CompletedNCT04851873Phase 3Results posted
• Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler DevicesCompletedNCT02596009Phase 4Results posted
• An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203CompletedNCT02573467Phase 3Results posted
• A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core StudyCompletedNCT02468674Phase 2Results posted
• Dose Range Finding Study of Bimagrumab in SarcopeniaCompletedNCT02333331Phase 2Results posted
• Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture SurgeryCompletedNCT02152761Phase 2Results posted
• Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM PatientsCompletedNCT01925209Phase 2/3Results posted
• BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With CachexiaCompletedNCT01669174Phase 2Results posted
• Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical TrialsActive, not recruitingNCT05335876Phase 3